Daiichi Sankyo Company, Limited (DSNKY)
OTCMKTS
· Delayed Price · Currency is USD
23.78
-0.67 (-2.74%)
Mar 31, 2025, 3:59 PM EST
Daiichi Sankyo Company Revenue
Daiichi Sankyo Company had revenue of 484.84B JPY in the quarter ending December 31, 2024, with 8.48% growth. This brings the company's revenue in the last twelve months to 1.80T, up 19.46% year-over-year. In the fiscal year ending March 31, 2024, Daiichi Sankyo Company had annual revenue of 1.60T with 25.28% growth.
Revenue (ttm)
1,795.99B JPY
Revenue Growth
+19.46%
P/S Ratio
n/a
Revenue / Employee
95.91M JPY
Employees
18,726
Market Cap
44.01B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 1,601.69B | 323.21B | 25.28% |
Mar 31, 2023 | 1,278.48B | 233.59B | 22.36% |
Mar 31, 2022 | 1,044.89B | 82.38B | 8.56% |
Mar 31, 2021 | 962.52B | -19.28B | -1.96% |
Mar 31, 2020 | 981.79B | 52.08B | 5.60% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.76B |
SS Innovations International | 16.04M |
Veradigm | 588.02M |
Elite Pharmaceuticals | 70.00M |
Glass House Brands | 200.90M |
Northwest Biotherapeutics | 1.60M |
Silence Therapeutics | 43.26M |
American Oncology Network | 1.76B |
Daiichi Sankyo Company News
- 10 days ago - Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed - Benzinga
- 20 days ago - Nosis Biosciences Announces Research Collaboration and Option Agreement with Daiichi Sankyo to Develop Cell-Targeted RNA Medicines - Business Wire
- 4 weeks ago - Daiichi Sankyo and AstraZeneca report positive result in trial for its gastric cancer treatment - Seeking Alpha
- 4 weeks ago - ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with HER2 Positive Metastatic Gastric Cancer at Interim Analysis of DESTINY-Gastric04 Phase 3 Trial - Benzinga
- 4 weeks ago - AstraZeneca's metastatic breast cancer treatment gets EU recommendation - Seeking Alpha
- 2 months ago - AstraZeneca Blames 'Toxic' Climate As It Walks Away from Over $550 Million UK Vaccine Plant - Benzinga
- 2 months ago - Q3 2025 Daiichi Sankyo Co Ltd Earnings Presentation Transcript - GuruFocus
- 2 months ago - Incoming Daiichi Sankyo CEO shares business roadmap going forward - CNBC